Immuneel Therapeutics, an India-based biotech firm developing cell and gene therapies has raised $15 million in its Series A funding round co-led by Eight Road Ventures, True North, and F-Prime Capital.

  • The firm is working on developing its own pipeline of chimeric antigen receptor T-Cell (CAR-T) therapies and other cellular immunotherapies for management and treatment of cancer.
  • The fund will be used to support the development of the pipeline and its improvement.
  • It last raised $15 million from UHNI, a VC firm based in the US.